

Curriculum Vitae

Name: ANDREADOU, IOANNA

Professional address:

Laboratory of Pharmacology
School of Pharmacy, National and Kapodistrian
University of Athens
Panepistimiopolis, 15771 Zografou
Tel: (30) 2107274827 Fax: (30) 2107274747
email: jandread@pharm.uoa.gr

Home address:

6-8 Menemenis Str
16122 Kesariani, Athens
Tel: (30) 2107290879

IDENTIFIERS

ORCID ID: 0000-0003-1504-9942

Google Scholar Profile: Ioanna Andreadou

Place of birth: Athens

Current position

Associate Professor, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens

EDUCATION

- 1988 Degree in Pharmacy, Aristotle's University of Thessaloniki.
- 1994 PhD in Medicinal Chemistry Aristotle's University of Thessaloniki.
- 1994-1996 Post-doctoral training (Leiden Amsterdam Center for Drug Research, Vrije Universiteit Amsterdam, Div. of Molecular Pharmacology and Toxicology).
- PhD Thesis: Synthesis of novel anti-inflammatory compounds with basic character: correlation of structural characteristics with activity upon free radicals, drug metabolism and inflammation.
- PostDoc Thesis: Mechanism based design of novel Se-substituted selenocysteine derivatives as potential kidney selective prodrugs.

FELLOWSHIPS

- 1988-1991 **IKY**, State Scholarship Foundation, Athens (Greece)
- 1994 **Human Capital and Mobility** (Leiden, the Netherlands)
- 1995 **European Science Foundation** (Strasbourg France)
- 2009 **Hellenic Society of Cardiology** (Greece) THE HATTER CARDIOVASCULAR INSTITUTE, Research Department of Cardiovascular Medicine, Division of Medicine, University College London Hospital & Medical School.

RESEARCH INTERESTS

- Pharmacology- Cardiovascular pharmacology.
- Pre-clinical drug screening.
- Oxidative stress in ischemia – reperfusion injury.
- Molecular toxicology.

RESEARCH AND PROFESSIONAL CARRER

2016-	Associate Prof. of Pharmacology, Pharmaceutical Chemistry Division, School of Pharmacy, National and Kapodistrian Univ. of Athens.
2011-2016	Assistant Prof. of Pharmacology, Pharmaceutical Chemistry Division, School of Pharmacy, National and Kapodistrian Univ. of Athens.
2006-2011	Lecturer of Pharmacology, Pharmaceutical Chemistry Division, School of Pharmacy, National and Kapodistrian Univ. of Athens.
2003-2006	Teaching Associate, School of Pharmacy, National and Kapodistrian Univ. of Athens
2005-today	Research fellow, B' University Dept. of Cardiology, Medical School, Attikon General Hospital, Athens
1998-2005	Clinical Reasearch Accosiate Manager INTERACT (International Academic Coordination of Trials)
1996-1998	ELPEN Pharmaceutical Company: R & D Department

CLINICAL TRIALS

- **1998-2005** Clinical Reasearch Accosiate Manager INTERACT (International Academic Coordination of Trials):
- **EUROPA 1/1/1998 –30/12/2003:** EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery (EUROPA) disease.
- **PERFECT:** Sub-study: PERindopril-Function of the Endothelium in Coronary Artery Disease Trial
- **PERSPECTIVE:** Perindopril's prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation.
- **SOTI:** The Spinal Osteoporosis Therapeutic Intervention (SOTI):Strontium ranelate: short- and long-term benefits for post-menopausal women with osteoporosis.
- **TROPOS:** Strontium Ranelate Reduces the Risk of Nonvertebral Fractures in Postmenopausal Women with Osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study.
- **PREAMI 5/2000 – 12/2003:** *Perindopril and Remodelling in Elderly with Acute Myocardial Infarction.*
- **3/2000-2005: CARISA:***A double-blind, randomized, stratified, placebo-controlled, parallel study of Ranolazine SR at doses of 750 mg twice a day and 1000 mg twice a day in combination with other anti-anginal medications in patients with chronic stable angina pectoris.*

EXPERT EVALUATOR OF EUROPEAN RESEARCH GRANDS

- 1.Executive Board of the Austrian Science Fund I, FWF, Project number: P2289-B18.
2. Expert Evaluator of H2020 **Marie Skłodowska-Curie Initial Training Networks** (ITN), February-March 2015.
3. Expert Evaluator of **Marie Skłodowska-Curie Individual Fellowships**H2020-MSCA-IF-2015, October-November 2015.
4. Expert Evaluator of H2020 **Marie Skłodowska-Curie Initial Training Networks** (ITN), February-March 2016.
5. Expert Evaluator of **Marie Skłodowska-Curie Individual Fellowships**H2020-MSCA-IF-2016, October-November 2016.
6. Expert Evaluator of H2020 **Marie Skłodowska-Curie Initial Training Networks** (ITN), February-March 2017.
7. Expert Evaluator of **Marie Skłodowska-Curie Individual Fellowships**H2020-MSCA-IF-2017, October-November 2017.

8. Expert Evaluator of **Marie Skłodowska-Curie Individual Fellowships**H2020-MSCA-IF-2018, October-November 2018.
9. Expert evaluator in Doctoral INPhINIT Fellowship Programme, promoted by “la Caixa” Foundation, 2019.

VISITING PROFESSORSHIPS

2017 Visiting Professor in Dept. of Medical Sciences, University of Turin

EDITORIAL BOARD MEMBER, GUEST EDITOR AND AD-HOC REVIEWER

Editorial Board Member: British Journal of Pharmacology, Basic Research in Cardiology (IF: 6.470), International Journal of Molecular Sciences (IF: 4.183), J Cardiovasc Pharmacol Ther (IF: 2.570).

Guest Editor: *International Journal of Molecular Sciences*: Special Issue "Novel Molecular Targets for Cardioprotection: The EU-CARDIOPROTECTION COST Action (CA16225)" (Special Issue Editors: Ioanna Andreadou, Derek Hausenloy, Hector A. Cabrera Fuentes).

Cardiovascular Research: Cardiovascular Research Spotlight Issue on: Cardioprotection beyond the cardiomyocyte (Special Issue Editors: Derek Hausenloy, Sean Davidson, Ioanna Andreadou, David Garcia-Dorado).

British Journal of Pharmacology: Themed Issue: Risk factors, comorbidities, and comedications in cardioprotection (Guest Editors: Rainer Schulz, Ioanna Andreadou, Derek J Hausenloy, and Péter Ferdinandy).

Frontiers in Pharmacology: Themed Issue: The challenge of new therapeutic approaches for unmet therapeutic need (Special Issue Editors: Ioanna Andreadou, Ariana Carolina Rosa, Mitsunobo Mio).

Ad hoc reviewer for >40 journals including Circulation, Theranostics, British Journal of Pharmacology, Cardiovascular Research, European Journal of Heart Failure, Free Radical Biology & Medicine, Basic Research in Cardiology, International Journal of Cardiology, Journal of Leukocyte Biology, Journal of Nutrition, Journal of Pharmacology Experimental Therapeutics, Oxidative Medicine and Cellular Longevity, Pharmacology Research, PLOS ONE.

MEMBER OF SCIENTIFIC COUNCILS IN GREEK AUTHORITIES

2016-Today: Member of the Scientific Council for Drug Approvals [National Drug Organization (EOF)]

2014-Today: Member of the Scientific Council of Narcotics, Ministry of Health

MEMBERSHIP OF SCIENTIFIC COMMITTEES

1. **Vice President** of Hellenic Society of Basic and Clinical Pharmacology.
2. Member of the Administration Board of the Working Group of Basic and Translational Cardiology. (HellenicSocietyofCardiology).
3. 2010: European Cardiology Society, **Working Group: Cardiovascular Pharmacology**.
4. 2015: **ISHR (International Society for Heart Research)**.
5. 1998-2008: Membership of the Administration Board of the Hellenic Society of Pharmacology (Member of European Federation of Medicinal Chemistry, and Member of EUFEPS)
6. 1998: Hellenic Society of Free Radicals and Oxidative Stress (Member of International Society for Free Radical Research)
7. 1998: Hellenic Society of Pharmacists
8. 1/1998: Hellenic Society of Pharmaceutical Medicine (ELEFI)
9. 02/2000: Hellenic Pharmaceutical Society (EFE)

TEACHING ACTIVITIES

1. Pharmacology I
2. Pharmacology II
3. Advanced Pharmacology, Master Sciences Degree in “Drug Design and Development”, specialization “Pharmacology”.
4. Clinical Pharmacology, Master Sciences Degree in Clinical Pharmacy”.
5. Pharmaceutical Analysis Laboratory training of 4th year students. Department of Pharmacy of Pharmacy, University of Athens (2013-2015).
6. Pharmacology, Master Sciences Degree in “Intensive Care Units and emergency nursing”, Medical School, University of Athens.
7. Pharmaceutical Technology Laboratory training of 4th year students. Department of Pharmacy of Pharmacy, University of Athens, 2003-2004, 2004-2005.
8. Seminars for the education of medical practitioners (cardiologists) in the protocols of the clinical studies.
9. Laboratory training of molecular pharmacology, toxicology, minor programs of the 4th year students of Vrije University of Amsterdam, 1992-1994.
10. Pharmaceutical Chemistry Laboratory training, Department of Pharmacy, Aristotelis University of Thessaloniki, 1990-1993.

LIST OF RESEARCH PROJECTS

1. “Development of an economically viable process for the integrated management of winemaking industry waste; production of high added value natural products”
Budget: 1.316.423€, LIFE 03 ENV/GR/000223 DIONYSOS, Participant, 2003-2006
AWARD TOP-5 BEST of the BEST Life projects in EU for 2007-2008
2. “Development of novel molecules, analogues of nicorandil and adenosine as ischemic preconditioning pharmacological triggers”. Budget: 15.000€, Hellenic Society of Cardiology
Principal investigator, 2007-2009
3. “Design and synthesis of novel molecules as pharmacological postconditioning triggers”, Budget: 3.000 €, Hellenic Society of Cardiology, **Principal investigator**, 2008-2010
4. “Effect of the olive oil constituent, oleuropein on chronic heart failure induced by adriamycin: investigation of the molecular mechanism”, Budget: 8.000 €, Ministry of Health, Participant, 2009-2011
5. “Investigation of the antiatheromatic and cardioprotective activities of olive constituents, oleuropein and oleocanthal”, Budget: 8.000 €, Hellenic Society of Cardiology, **Principal investigator**, 2010-2012
6. Cost-Action FA0602-Bioactive Food Components, Mitochondrial Function and Health, Substituted member, 2007-2011
7. Cost-Action actions BM1005-Gasotransmitters: from basic science to therapeutic applications. Management Committee Member, 2011-2015
8. “GSK3 β as molecular target of myocardial infarct size reduction: study of its inhibition during reperfusion in vivo”, Budget: 5.000 €, Hellenic Society of Cardiology, **Principal investigator**, 2012-2014
9. Cost Action EU-ROS (2012-2016): The European Network on Oxidative Stress and Redox Biology Research, Management Committee Member, 2012-2016
10. “In vitro characterization and in vivo PK/PD study of the bioactive constituents of Crocus sativus (*Iridaceae*): investigation of antiatheromatic and cardioprotective effects and the development of per-os pharmaceutical formulation. (School of Pharmacy and UNIPHARMA)”, Budget: 240.000 € PAVET, Participant, 2013-2015

11. “Exploitation of edible plants rich in sulfur and phenolic compounds in the development of drugs and food supplements. (School of Pharmacy, Help, Galenica)”, Budget: 310.093,80 €, PAVET, Participant, 2013-2015
12. “Study of a new mechanism of myocardial infarct size reduction of nitroglycerin”, Budget: 5.000 € Hellenic Society of Cardiology, **Principal investigator**, 2015-2017
13. “Preclinical study of dose-response effectiveness of the potassium canrenoate, exenatide and cyclosporine in an in vivo mice model of ischemia/reperfusion injury”, Genesis Pharma, **Principal investigator**, Budget: 35.000€, 2016
14. Cost Action EU-Cardioprotection, **Working Group Leader**, 2017-2021.
15. “Study of the antioxidant effect of isolated compounds and extracts derived from Olea Europa”, Budget: 8.000 €, Kleon Tsetis Foundation Scientific Research & Culture, **Principal investigator**, 2018
16. “Dairy Products Supplemented with Natural Compounds from Epirus”, Budget: 64.327,40€, Operational Program of the Region of Epirus 2014-2020, **Principal investigator**, 2018-2020
17. “Exploitation of Greek vineyards for the development of innovative pharmaceutical products for chronic venous insufficiency” (VITVIN), Budget: 998.925,20 €, Action "RESEARCH - CREATE - INNOVATE", Operational Programme Competitiveness, Entrepreneurship and Innovation 2014-2020 (EPAnEK), Participant, 2018-2021
18. “Study of the possible synergistic cardioprotective effect of oleuropein and post-conditioning mechanism in myocardial infarction”, Budget: 8.000 €, Kleon Tsetis Foundation Scientific Research & Culture, **Principal investigator**, 2019
19. “Development of an innovative- “scientific” intelligent- nutraceutical based on Olive constituents for patients with coronary artery disease and metabolic syndrome”, Budget: 250.042,50€, Action "RESEARCH - CREATE - INNOVATE", Operational Programme Competitiveness, Entrepreneurship and Innovation 2014-2020 (EPAnEK), **Principal investigator**, 2019-2021
20. “Investigating the mechanisms of Carfilzomib-induced myocardial dysfunction in animal models with comorbidities”, Budget:200.000€, Amgen, **Principal investigator**, 2019-2021

PUBLICATIONS IN PEER-REVIEWED JOURNALS (selected from 135, IF>5)

Andreadou I*, Iliodromitis E, Mikros E, Bofilis E, Zoga A, Constantinou M, Tsantili-Kakoulidou A, Kremastinos DT. Melatonin does not prevent the protection of ischemic preconditioning in vivo despite its antioxidant effect against oxidative stress. **Free Radic Biol Med**, 37: 500-510, 2004.

Avgeropoulou C, **Andreadou I***, Markantonis-Kyroudis S, Demopoulou M, Missovoulos P, Androulakis A, Kallikazaros I. The Ca²⁺-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. **Eur J Heart Fail**, 7:882-887, 2005.

Sigala F, Theocharis S, Sigalas K, Markantonis-Kyroudis S, Papalabros E, Triantafyllou A, Kostopanagiotou G, **Andreadou I.*** Therapeutic effect of melatonin in an experimental model of liver injury and regeneration. **J Pineal Research**, 40: 270-279, 2006.

Andreadou I*, Iliodromitis EK, Tsovolas K, Aggeli IK, Zoga A, Gaitanaki C, Markantonis S, Beis I, Kremastinos DTh. Acute administration of Vitamin E triggers preconditioning via KATP channels and cyclic-GMP without inhibiting lipid peroxidation. **Free Radic Biol Med**, 41: 1092-1099, 2006.

Andreadou I*, Sigala F, Iliodromitis EK, Papaefthimiou M, Sigalas C, Aligiannis N, Savvari P, Gorgoulis V, Papalabros E, Kremastinos DTh. Acute doxorubicin cardiotoxicity is successfully treated

with the phytochemical oleuropein through suppression of oxidative and nitrosative stress. **J Mol Cell Cardiol**, 42: 549-558, 2007.

Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaïdis I, **Andreadou I**, Kaplanoglou T, Katsibri P, Skarantavos G, Soukakos PN, Kremastinos DTh. Inhibition of interleukin-1 by Anankira improves vascular and left ventricular function in patients with rheumatoid arthritis. **Circulation**, 117:2662-2269, 2008

Ikonomidis I, Tzortzis S, Lekakis J, Paraskevaïdis I, **Andreadou I**, Nikolaou M, Kaplanoglou T, Katsimbri P, Skarantavos G, Soucacos P, Kremastinos DT. Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. **Heart**, 95: 1502-7, 2009.

Iliodromitis EK, **Andreadou I***, Prokovas E, Zoga A, Farmakis D, Fotopoulou T, Ioannidis K, Paraskevaïdis IA, Kremastinos DTh. Simvastatin in contrast to postconditioning reduces infarct size in hyperlipidemic rabbits: possible role of oxidative/nitrosative stress. **Basic Res Cardiol**, 105:193-203, 2010.

Ikonomidis I, Iliodromitis EK, Tzortzis S, Antoniadis A, Paraskevaïdis I, **Andreadou I**, Fountoulaki K, Farmakis D, Kremastinos DT, Anastasiou-Nana M. Staccato reperfusion improves myocardial microcirculatory function and long-term left ventricular remodelling: A randomized contrast echocardiography study. **Heart**, 96: 1898-1903, 2010.

Ikonomidis I, Tzortzis S, Lekakis J, Paraskevaïdis I, Dasou P, Parissis J, Nikolaou M, Markantonis SL, Katsimbri P, Skarantavos G, **Andreadou I***, Anastasiou-Nana M. Association of soluble apoptotic markers with impaired left ventricular deformation in patients with rheumatoid arthritis. Effects of inhibition of interleukin-1 activity by anakinra. **Thromb Haemost**, 106: 959-967, 2011.

Farmakis D, **Andreadou I**, Aessopos A. High-sensitivity troponin assays: ready for prime-time use as surrogates of subclinical myocardial injury? **J Am Coll Cardiol**, 60(2):166, 2012.

Andreadou I*, Farmakis D, Prokovas E, Sigala F, Zoga A, Spyridaki K, Papalois A, Papapetropoulos A, Anastasiou-Nana M, Kremastinos DTh, Iliodromitis EK. Short-term statin administration in hypercholesterolemic rabbits resistant to postconditioning: effects on infarct size, endothelial nitric oxide synthase and nitro-oxidative stress. **Cardiovasc Res**, 94: 501-509, 2012.

Andreadou I*, Mikros E, Ioannidis K, Sigala F, Naka K, Kostidis S, Farmakis D, Tenta R, Kavantzias N, Bibli S-I, Gikas E, Skaltsounis L, Kremastinos DTh, Iliodromitis EK. Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism. **J Mol Cell Cardiol**, 69:4-16, 2014.

Ikonomidis I, Tzortzis S, **Andreadou I**, Paraskevaïdis I, Katseli C, Katsimbri P, Parissis J, Anastasiou-Nana M, Lekakis J. Increased benefit of interleukin 1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. **Circulation: Cardiovascular Imaging**, 7(4):619-628, 2014.

Andreadou I*, Iliodromitis EK, Rassaf T, Schulz R, Papapetropoulos A, Ferdinandy P. The role of gasotransmitters NO, H₂S, CO in myocardial ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. **Brit J Pharmacol**, 172: 1587-1606, 2015.

Andreadou I*, Bibli S-I, Mastromanolis E, Zoga A, Efentakis P, Papaioannou N, Farmakis D, Kremastinos DTh, Iliodromitis EK. Transient carotid ischemia as a remote conditioning stimulus on

myocardial infarction size in anesthetized rabbits: insights into the intracellular signalling. **Int J Cardiol**, 184C:140-151,2015.

Bibli S-I, **Andreadou I***, Chatzianastasiou A, Tzimas C, Sanoudou D, Kranias E, Brouckaert P, Coletta C, Szabo C, Kremastinos DTh, Iliodromitis EK, Papapetropoulos A. Cardioprotection by H₂S engages a cGMP-dependent protein kinase G/phospholamban pathway. **Cardiovasc Res**, 106(3):432-42, 2015.

Andreadou I, Iliodromitis EK, Szabo C, Papapetropoulos A. Hydrogen sulfide and PKG in ischemia-reperfusion injury: sources, signaling, accelerators and brakes. **Basic Res Cardiol**, 110:52, 2015.

Lougiakis N, Papapetropoulos A, Gikas E, Toumpas S, Efentakis P, Wedmann R, Zoga A, Zhou Z, Iliodromitis EK, Skaltsounis A-L, Filipovic MR, Pouli N, Marakos P, **Andreadou I***. Synthesis and pharmacological evaluation of novel adenine-hydrogen sulfide slow release hybrids designed as multi-target cardioprotective agents. **J Med Chem**, 59(5):1776-90, 2016.

I. Andreadou*, E.K. Iliodromitis, A. Lazou, A. Görbe, Z. Giricz, R. Schulz, P. Ferdinandy. Effect of hypercholesterolemia on myocardial function, ischemia-reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning. **Br J Pharmacol**, 174(12):1555-1569, 2017.

Bibli S-I, Zhou Z, Zukunft S, Fisslthaler B, **Andreadou I**, Szabo C, Brouckaert P, Fleming I, Papapetropoulos A. Tyrosine phosphorylation of eNOS regulates myocardial survival after an ischemic insult: role of PYK2 **Cardiovasc Res**, 113:926-937, 2017.

Sigala F, Efentakis P, Karageorgiadi D, Filis K, Zampas P, Iliodromitis EK, Zografos G, Papapetropoulos A, **Andreadou I***. Reciprocal regulation of eNOS, H₂S and CO-synthesizing enzymes in human atheroma: Correlation with plaque stability and effects of simvastatin. **Redox Biol**, 12:70-81, 2017.

Ikonomidis I, Papadavid E, Makavos G, **Andreadou I**, Varoudi M, Gravanis K, Theodoropoulos K, Pavlidis G, Triantafyllidi H, Moutsatsou P, Panagiotou C, Parissis J, Iliodromitis E, Lekakis J, Rigopoulos D. Lowering Interleukin-12 Activity Improves Myocardial and Vascular Function Compared With Tumor Necrosis Factor- α Antagonism or Cyclosporine in Psoriasis. **Circ Cardiovasc Imag**, 10(9), pii: e006283, 2017.

Ikonomidis I, Vlastos D, Kourea K, Kostelli G, Varoudi M, Pavlidis G, Efentakis P, Triantafyllidi H, Parissis J, **Andreadou I**, Iliodromitis E, Lekakis J. Electronic cigarette smoking increases arterial stiffness and oxidative stress to a lesser extent than a single conventional cigarette: an acute and chronic study. **Circulation**, 137:303–306, 2018.

Lambadiari V, Pavlidis G, Kousathana F, Varoudi M, Vlastos D, Maratou E, Georgiou D, **Andreadou I**, Parissis J, Triantafyllidi H, Lekakis J, Iliodromitis E, Dimitriadis G, Ikonomidis I. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes. **Cardiovasc Diabetol**, 17(1):8, 2018.

Bøtker HE, Hausenloy D, **Andreadou I**, Antonucci S, Boengler K, Davidson SM, Deshwal S, Devaux Y, Di Lisa F, Di Sante M, Efentakis P, Femminò S, Dorado D-G, Giricz Z, Ibanez B, Iliodromitis E, Kaludercic N, Kleinbongard P, Neuhäuser M, Ovize M, Pagliaro P, Rahbek-Schmidt M, Ruiz-Meana M, Schlüter K-D, Schulz R, Skyschally A, Wilder C, Yellon DM, Ferdinandy P, Heusch G. Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection*. **Basic Res Cardiology**, 113(5):39, 2018.

Bibli S-I, Papapetropoulos A, Iliodromitis EK, Daiber A, Randriamboavonjy V, Steven S, Brouckaert P, Chatzianastasiou A, Kypreos KE, Hausenloy DJ, Fleming I, **Andreadou I***. Nitroglycerin limits infarct size through S-nitrosation of Cyclophilin D: A novel mechanism for an old drug. **Cardiovasc Res**, 115(3):625-636, 2019.

Davidson SM, Ferdinandy P, **Andreadou I**, Bøtker HE, Heusch G, Ibáñez B, Ovize M, Schulz R, Yellon DM, Hausenloy DJ, Garcia-Dorado D. Multi-target strategies to reduce myocardial ischemia/reperfusion injury. **J Am Coll Cardiol**, 73(1):89-99, 2019.

Davidson SM, **Andreadou I**, Barile L, Birnbaum Y, Cohen MV, Cabrera-Fuentes H, Downey JM, Girao H, Pagliaro P, Penna C, Pernow J, Preissner K, Ferdinandy P. Circulating blood cells and extracellular vesicles in acute cardioprotection. **Cardiovasc Res**, 115(7):1156-1166, 2019.

Efentakis P, Kremastiotis G, Varela A, Nikolaou P-E, Papanagnou E-D, Davos CH, Tsoumani M, Agrogiannis G, Konstantinidou A, Kastritis E, Kanaki Z, Iliodromitis EK, Klinakis A, Dimopoulos MA, Trougakos IP, **Andreadou I***, Terpos E. Molecular mechanisms of Carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of Metformin. **Blood**, 133(7):710-723, 2019.

Andreadou I*, Cabrera-Fuentes HA, Devaux Y, Frangogiannis NG, Frantz S, Guzik T, Liehn E, da Costa Gomes CP, Schulz R, Hausenloy DJ. Immune cells as targets for cardioprotection: New players and novel therapeutic opportunities. **Cardiovasc Res**, 115, 1117–1130, 2019.

Nikolaou PE, Boengler K, Efentakis P, Vougioukianopoulou K, Zoga A, Gaboriaud-Kolar N, Myriantopoulos V, Alexakos P, Kostomitsopoulos N, Rerras I, Tsantil-Kakoulidou A, Skaltsounis AL, Papapetropoulos A, Iliodromitis EK, Schulz R, **Andreadou I***. Investigating and re-evaluating the role of GSK3beta kinase as a molecular target for cardioprotection by using novel pharmacological inhibitors. **Cardiovasc Res**, 115, 1228–1243, 2019.

Efentakis P, Varela A, Chavdoula E, Sigala F, Sanoudou D, Tenta R, Gioti K, Kostomitsopoulos N, Papapetropoulos A, Tasouli A, Farmakis D, Davos CH, Klinakis A, Suter T, Cokkinos DV, Iliodromitis EK, Wenzel P, **Andreadou I***. Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose dependent manner: Implications for inotropy. **Cardiovasc Res**, in press.

Lambadiari V, Pavlidis G, Kousathana F, Maratou E, Georgiou D, **Andreadou I**, Kountouri A, Varoudi M, Balampanis K, Parissis J, Triantafyllidi H, Katogiannis K, Birba D, Lekakis J, Dimitriadis G, Ikonomidis I. Effects of Different Antidiabetic Medications on Endothelial Glycocalyx, Myocardial Function, and Vascular Function in Type 2 Diabetic Patients: One Year Follow-Up Study. **J Clin Med**, 8(7). pii: E983, 2019.

NUMBER OF CITATIONS IN THE LITERATURE: 4.827; h-index: 38 (Google Scholar)

Citations the last 5 years: 2658; h-index: 28

Publications: 135 (131 listed in PubMed)

1st, 2nd, senior and Corresponding author: 75

Book Chapters: 3, Patent: 1